| Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma JH Sampson, AB Heimberger, GE Archer, KD Aldape, AH Friedman, ... Journal of clinical oncology 28 (31), 4722-4729, 2010 | 899 | 2010 |
| Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma PE Fecci, DA Mitchell, JF Whitesides, W Xie, AH Friedman, GE Archer, ... Cancer research 66 (6), 3294-3302, 2006 | 650 | 2006 |
| Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients DA Mitchell, KA Batich, MD Gunn, MN Huang, L Sanchez-Perez, SK Nair, ... Nature 519 (7543), 366-369, 2015 | 560 | 2015 |
| Proteomic and immunologic analyses of brain tumor exosomes MW Graner, O Alzate, AM Dechkovskaia, JD Keene, JH Sampson, ... The FASEB Journal 23 (5), 1541, 2009 | 508 | 2009 |
| Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma DA Mitchell, W Xie, R Schmittling, C Learn, A Friedman, RE McLendon, ... Neuro-oncology 10 (1), 10-18, 2008 | 451 | 2008 |
| Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function PE Fecci, H Ochiai, DA Mitchell, PM Grossi, AE Sweeney, GE Archer, ... Clinical cancer research 13 (7), 2158-2167, 2007 | 384 | 2007 |
| Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma JH Sampson, KD Aldape, GE Archer, A Coan, A Desjardins, AH Friedman, ... Neuro-oncology 13 (3), 324-333, 2011 | 382 | 2011 |
| An epidermal growth factor receptor variant III–targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme JH Sampson, GE Archer, DA Mitchell, AB Heimberger, JE Herndon, ... Molecular cancer therapeutics 8 (10), 2773-2779, 2009 | 342 | 2009 |
| A large language model for electronic health records X Yang, A Chen, N PourNejatian, HC Shin, KE Smith, C Parisien, ... NPJ digital medicine 5 (1), 194, 2022 | 289 | 2022 |
| Long-term survival in glioblastoma with cytomegalovirus pp65-targeted vaccination KA Batich, EA Reap, GE Archer, L Sanchez-Perez, SK Nair, ... Clinical Cancer Research 23 (8), 1898-1909, 2017 | 277 | 2017 |
| CXCR1-or CXCR2-modified CAR T cells co-opt IL-8 for maximal antitumor efficacy in solid tumors L Jin, H Tao, A Karachi, Y Long, AY Hou, M Na, KA Dyson, AJ Grippin, ... Nature communications 10 (1), 4016, 2019 | 265 | 2019 |
| CCR2 inhibition reduces tumor myeloid cells and unmasks a checkpoint inhibitor effect to slow progression of resistant murine gliomas JA Flores-Toro, D Luo, A Gopinath, MR Sarkisian, JJ Campbell, IF Charo, ... Proceedings of the National Academy of Sciences 117 (2), 1129-1138, 2020 | 257 | 2020 |
| RNA-transfected dendritic cells in cancer immunotherapy DA Mitchell, SK Nair The Journal of clinical investigation 106 (9), 1065-1069, 2000 | 248 | 2000 |
| Temozolomide for immunomodulation in the treatment of glioblastoma A Karachi, F Dastmalchi, DA Mitchell, M Rahman Neuro-oncology 20 (12), 1566-1572, 2018 | 236 | 2018 |
| Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma JH Sampson, GE Archer, DA Mitchell, AB Heimberger, DD Bigner Seminars in immunology 20 (5), 267-275, 2008 | 218 | 2008 |
| Increased proportion of FoxP3+ regulatory T cells in tumor infiltrating lymphocytes is associated with tumor recurrence and reduced survival in patients with glioblastoma EJ Sayour, P McLendon, R McLendon, G De Leon, R Reynolds, J Kresak, ... Cancer Immunology, Immunotherapy 64, 419-427, 2015 | 215 | 2015 |
| Systemic anti-CD25 monoclonal antibody administration safely enhances immunity in murine glioma without eliminating regulatory T cells PE Fecci, AE Sweeney, PM Grossi, SK Nair, CA Learn, DA Mitchell, X Cui, ... Clinical Cancer Research 12 (14), 4294-4305, 2006 | 210 | 2006 |
| Therapeutic modulation of phagocytosis in glioblastoma can activate both innate and adaptive antitumour immunity CA von Roemeling, Y Wang, Y Qie, H Yuan, H Zhao, X Liu, Z Yang, ... Nature communications 11 (1), 1508, 2020 | 178 | 2020 |
| Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma BD Choi, CT Kuan, M Cai, GE Archer, DA Mitchell, PC Gedeon, ... Proceedings of the National Academy of Sciences 110 (1), 270-275, 2013 | 174 | 2013 |
| The effects of new or worsened postoperative neurological deficits on survival of patients with glioblastoma M Rahman, J Abbatematteo, EK De Leo, PS Kubilis, S Vaziri, F Bova, ... Journal of neurosurgery 127 (1), 123-131, 2016 | 169 | 2016 |
